Skip to content
Events

Details

The application of genomics technology for analysis of liquid biopsy samples is rapidly growing. In particular, cell-free DNA (cfDNA) is the analyte that has the potential to reveal detailed information on disease progression. 

Tune in to our 3-part video series

  • Multiomic analysis of liquid biopsy samples

                Anna Babayan, Illumina

  • Cell-free DNA Prep with Enrichment library prep kit

                Mariela Cuadras, Illumina

  • Whole exome sequencing of cfDNA in metastatic prostate cancer – customer presentation

                Tina Moser, MedUni Graz

Complete the form to access the video recordings

Your email address is never shared with third parties.

Date & Time
16 Apr 2024
Topic
Cancer research
Watch Now
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see emea.illumina.com/company/legal.html.

© 2024 Illumina, Inc. All rights reserved.